China Drug Development Trends – Pipeline Drugs, Key Players and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Reasons to buy the ‘China Drug Development Trends’ report:

  • Study objectives of the report.
  • Analyze China’s drug development activities, including the most promising agents.
  • Explore the growth of CAR-T cell and ADC therapies in this market.
  • Examine the role of China’s regulatory environment in accelerating the approval of innovative therapies.
  • Assess the growth in clinical trials conducted in China.
  • Analyze deal-making activity trends.
  • Report design.

How is our ‘China Drug Development Trends’ report unique from other reports in the market?

  • Gain insights into China’s rapidly evolving drug development landscape, including key innovative therapies.
  • Understand the growth trajectory and market potential of CAR-T cell and ADC therapies in China.
  • Explore the impact of China’s regulatory reforms on the accelerated approval.
  • Stay informed on the increasing number of clinical trials conducted in China.
  • Identify emerging trends in deal-making activities and partnership opportunities.

We recommend this valuable source of information to anyone involved in:

  • ​​​​Drug Development and ​​​​Pharma/Biotech Companies – Value Chain
  • Pharmaceutical Industry Suppliers and Distributors
  • Pharma/Drug Manufacturing Companies – Leaders and Startups
  • Business Development and Market Intelligence
  • Investment Analysts and Portfolio Managers
  • Professional Services – Investment Banks, PE/VC Firms
  • M&A/Investment, Management Consultants, and Consulting Firms

To Get a Snapshot of the China Drug Development Trends Report

Download a Free Report Sample

China Drug Development Trends Report Overview

China’s drug development market has grown at a CAGR of more than 18% in 2024. Robust innovation has driven China to emerge as a critical player in global drug development. The pharmaceutical industry in the country has seen a surge in drug development activities in recent years, with an increasing focus on innovative therapies such as CAR-T cell and ADC therapies. This growth is also bolstered by a supportive regulatory environment that encourages innovation and expedites drug approvals. Alongside these developments, the number of clinical trials conducted within China has risen significantly and deal-making has intensified, further solidifying the country’s role in the global pharmaceutical landscape.

China drug development trends report explores the key metrics shaping the sector, including approved and pipeline drugs, and deal-making trends to assess its impact on the global pharmaceutical industry.

Buy the Full Report for More Insights into China’s Drug Development Trends, Download a Free Report Sample

Key Technology Areas ·       CAR-T

·       ADC

·       mRNA

·       siRNA

·       TCR

Key Deal Types ·       Venture Financing

·       Contract Service Agreement

·       Partnership

·       Licensing Agreement

·       Equity Offering

Key Competitors ·       Jiangsu Hengrui Medicine Co Ltd

·       CSPC Pharmaceutical Group Ltd

·       Simcere Pharmaceutical Group Ltd

·       Innovent Biologics Inc

·       Qilu Pharmaceutical Co Ltd

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

China Drug Development Trends - Technology Areas

A few of the key technology areas in the China drug development market are CAR-T, ADC, mRNA, siRNA, and TCR among others. The primary technology areas being explored by Chinese companies are CAR-T therapies. Currently, there are a significant number of oligonucleotide-based treatment modalities in development, with a prominent proportion focused on small interfering RNA (siRNA) therapies.

China Drug Development Market Analysis by Technology Area

China Drug Development Market Analysis by Technology Area

Buy the Full Report for More Technology Area Insights into China’s Drug Development Trends, Download a Free Report Sample

China Drug Development Trends – Deal Type

A few of the key deal types in the China drug development market are venture financing, contract service agreement, partnership, licensing agreement, and equity offering, among others. Venture financing is the predominant deal type in the market. Contract service agreement also had a significant share in the market.

China Drug Development Market Analysis by Deal Type

China Drug Development Market Analysis by Deal Type

Buy the Full Report for More Deal Type Insights into China’s Drug Development Trends, Download a Free Report Sample

China Drug Development Trends – Competitive Landscape

The major competitors in the China drug development market are Jiangsu Hengrui Medicine, CSPC Pharmaceutical Group, Simcere Pharmaceutical Group, Innovent Biologics Inc, and Qilu Pharmaceutical Co Ltd, among others. Approximately 50% of the pipeline assets for these companies are in late-stage clinical trials (Phases II and later). Jiangsu Hengrui Medicine has a significant number of drugs in the pre-registration stage and in the clinical stages.

China Drug Development Market Analysis by Deal Type

China Drug Development Market Analysis by Deal Type

Buy the Full Report for More Competitor Insights into China’s Drug Development Trends, Download a Free Report Sample

China Drug Development Trends

  • Venture Financing
  • Contract Service Agreement
  • Partnership
  • Licensing Agreement
  • Equity Offering

Table of Contents

Table of Contents (PowerPoint Deck)

1 Executive Summary

1.1 Executive Summary

2 Introduction

2.1 Objectives and Design

3. Drug Development Trends

3.1 Companies Based in China Have Made a Significant Impact on Global Drug Development

3.2 Companies Based in China Have Shown Steady Growth in Drug Development Activity

3.3 Companies Based in China Show a Higher Growth Rate for Drugs in All Stages of Development

3.4 The Most Drug Development Activity Is in Oncology, Both in the US and China

3.5 CAR-T Cell Therapies and ADC Therapies Dominate the Technological Advancement for Drugs Development in China

3.6 Top 10 Companies in China Have Approximately Half of Their Pipeline Assets in Late-Stage Clinical Development

3.7 Surge in Approvals in 2023–24 Can Be Attributed to Strong Support from China’s Regulatory Environment

3.8 Chinese Markets Are Expected to Embrace Several Promising Assets in Development

3.9 Pharma Deals Activity

3.10 Venture Financing Dominates the Funding for Drug Development in China

3.11 Clinical Trials Conducted in China Have Increased Significantly

4 Summary of Key Findings

4.1 Key Takeaways

5 Appendix

5.1 Abbreviations

5.2 Related Reports

6 About the Authors

6.1 About the Authors

7 Contact Us

7.1 Contact US

7.2 A global network of offices

7.3 About GlobalData

7.4 A Connected Platform for a Dynamic World

7.5 Contact Us

Frequently asked questions

China Drug Development Trends – Pipeline Drugs, Key Players and Deals thematic reports
Currency USD
$1,495

Can be used by individual purchaser only

$2,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

China Drug Development Trends – Pipeline Drugs, Key Players and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at China Drug Development Trends – Pipeline Drugs, Key Players and Deals in real time.

  • Access a live China Drug Development Trends – Pipeline Drugs, Key Players and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.